Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Cited by (4,475)

Items 101–200 of 4,475

1. Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia
   Parhofer, Klaus G. · 2015 · Diabetes & Metabolism Journal
2. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary
   Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2017 · Endocrine Practice
3. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
   American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., Aleppo, Grazia, Bannuru, Raveendhara R., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R., Ekhlaspour, Laya, Hilliard, Marisa E., Johnson, Eric L. et al. · 2024 · Diabetes Care
4. Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
   Dalton Bertolim Précoma, Gláucia Maria Moraes de Oliveira, Antônio Felipe Leite Simão, Óscar Pereira Dutra, Otávio Rizzi Coelho-Filho, Maria Cristina de Oliveira Izar, Rui Póvoa, Isabela de Carlos Back Giuliano, Aristóteles Comte de Alencar Filho, Carlos Alberto Machado et al. · 2019 · Arquivos Brasileiros de Cardiologia
5. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome
   Le Wang, Hongliang Cong, Jingxia Zhang, Yuecheng Hu, Ao Wei, Ying-yi Zhang, Hua Yang, Libin Ren, Wei Qi, Wenyu Li et al. · 2020 · Cardiovascular Diabetology
6. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
   Giugliano, Robert P., Cannon, Christopher P., Blazing, Michael A., Nicolau, José C., Corbalán, Ramón, Špinar, Jindřich, Park, Jeong-Gun, White, Jennifer A., Bohula, Erin A., Braunwald, Eugene · 2018 · Circulation
7. Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis
   Lotta, Luca A., Sharp, Stephen J., Burgess, Stephen, Perry, John R. B., Stewart, Isobel D., Willems, Sara M., Luan, Jian’an, Ardanaz, Eva, Arriola, Larraitz, Balkau, Beverley et al. · 2016 · JAMA
8. Safety and efficacy of statin therapy
   Adhyaru, Bhavin B., Jacobson, Terry A. · 2018 · Nature Reviews Cardiology
9. A Test in Context
   Ridker, Paul M · 2016 · Journal of the American College of Cardiology
10. Vascular Complications of Diabetes
    Joshua A. Beckman, Mark A. Creager · 2016 · Circulation Research
11. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting
    Josefin Soppert, Michael Lehrke, Nikolaus Marx, Joachim Jankowski, Heidi Noels · 2020 · Advanced Drug Delivery Reviews
12. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
    O’Donoghue, Michelle L., Giugliano, Robert P., Wiviott, Stephen D., Atar, Dan, Keech, Anthony, Kuder, Julia F., Im, KyungAh, Murphy, Sabina A., Flores-Arredondo, Jose H., López, J. Antonio G. et al. · 2022 · Circulation
13. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
    Kazi, Dhruv S., Moran, Andrew E., Coxson, Pamela G., Penko, Joanne, Ollendorf, Daniel A., Pearson, Steven D., Tice, Jeffrey A., Guzman, David, Bibbins-Domingo, Kirsten · 2016 · JAMA
14. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
    Donald M. Lloyd‐Jones, Pamela Bowe Morris, Christie Mitchell Ballantyne, Kim K. Birtcher, David D. Daly, Sondra M. DePalma, Margo Minissian, Carl E. Orringer, Sidney C. Smith · 2017 · Journal of the American College of Cardiology
15. Genetics of Coronary Artery Disease
    Ruth McPherson, Anne Tybjærg‐Hansen · 2016 · Circulation Research
16. Lipid-reduction variability and antidrug-antibody formation with bococizumab
    Ridker, Paul M, Tardif, Jean-Claude, Amarenco, Pierre, Duggan, William, Glynn, Robert J., Jukema, J. Wouter, Kastelein, John J.P., Kim, Albert M., Koenig, Wolfgang, Nissen, Steven et al. · 2017 · New England Journal of Medicine
17. Diabetes and lipid metabolism
    Vasilios Gabriel Athyros, Michael N. Doumas, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Eleni Georgianou, Alexandra Katsimardou, Asterios I. Karagiannis · 2018 · HORMONES
18. PCSK9 inhibitors: clinical evidence and implementation
    Sabatine, Marc S. · 2019 · Nature Reviews Cardiology
19. Association Between Obesity and Cardiovascular Outcomes
    Haris Riaz, Muhammad Shahzeb Khan, Tariq Jamal Siddiqi, Muhammad Usman, Nishant P. Shah, Amit Goyal, Sadiya S. Khan, Farouk Mookadam, Richard A. Krasuski, Haitham M. Ahmed · 2018 · JAMA Network Open
20. Inflammation in acute myocardial infarction: the good, the bad and the ugly
    Michael A. Matter, Francesco Paneni, Peter Libby, Stefan Frantz, Barbara Elisabeth Stähli, Christian Templin, Alessandro Mengozzi, Yu-Jen Wang, Thomas M. Kündig, Lorenz Räber et al. · 2023 · European Heart Journal
21. Cholesterol Biosynthesis: A Mechanistic Overview
    Nuno M. F. S. A. Cerqueira, Eduardo F. Oliveira, Diana Gesto, Diogo Santos‐Martins, Cátia Moreira, Hari N. Moorthy, Maria João Ramos, Pedro Alexandrino Fernandes · 2016 · Biochemistry
22. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease
    Erin D. Michos, John William McEvoy, Roger Scott Blumenthal · 2019 · New England Journal of Medicine
23. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
    Leslie Cho, Melinda Baughman Davis, Islam Y. Elgendy, Kelly Epps, Kathryn J. Lindley, Puja K. Mehta, Erin D. Michos, Margo Minissian, Carl J. Pepine, Viola Vaccarino et al. · 2020 · Journal of the American College of Cardiology
24. Japanese Clinical Practice Guideline for Diabetes 2019
    Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe et al. · 2020 · Journal of Diabetes Investigation
25. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
    Bril, Fernando, Cusi, Kenneth · 2017 · Diabetes Care
26. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT
    Bohula, Erin A., Giugliano, Robert P., Cannon, Christopher P., Zhou, Jing, Murphy, Sabina A., White, Jennifer A., Tershakovec, Andrew M., Blazing, Michael A., Braunwald, Eugene · 2015 · Circulation
27. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
    American Diabetes Association Professional Practice Committee, ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Das, Sandeep R., Echouffo-Tcheugui, Justin B. et al. · 2025 · Diabetes Care
28. Using Mendelian Randomization to Improve the Design of Randomized Trials
    Ference, Brian A., Holmes, Michael V., Smith, George Davey · 2021 · Cold Spring Harbor Perspectives in Medicine
29. Diabetes mellitus: an overview of the types, symptoms, complications and management
    Linda M. Cloete · 2021 · Nursing Standard
30. 8. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2016 · Diabetes Care
31. A decade of genome-wide association studies for coronary artery disease: the challenges ahead
    Jeanette Erdmann, Thorsten Kessler, Loreto Muñoz Venegas, Heribert Schunkert · 2018 · Cardiovascular Research
32. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
    Byeong‐Keuk Kim, Sung‐Jin Hong, Yong‐Joon Lee, Soon Jun Hong, Kyeong Ho Yun, Bum‐Kee Hong, Jung Ho Heo, Seung‐Woon Rha, Yun‐Hyeong Cho, Seung‐Jun Lee et al. · 2022 · The Lancet
33. Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis
    Worthmann, Anna, John, Clara, Rühlemann, Malte C, Baguhl, Miriam, Heinsen, Femke-Anouska, Schaltenberg, Nicola, Heine, Markus, Schlein, Christian, Evangelakos, Ioannis, Mineo, Chieko et al. · 2017 · Nature Medicine
34. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults
    on behalf of the China Kadoorie Biobank Collaborative Group, Luanluan Sun, Robert Clarke, Derrick Bennett, Canqing Yu, Robin G. Walters, Michael Hill, Sarah Parish, Iona Y. Millwood, Zheng Bian et al. · 2019 · Nature Medicine
35. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
    Ray, Kausik K, Colhoun, Helen M, Szarek, Michael, Baccara-Dinet, Marie, Bhatt, Deepak L, Bittner, Vera A, Budaj, Andrzej J, Diaz, Rafael, Goodman, Shaun G, Hanotin, Corinne et al. · 2019 · The Lancet Diabetes & Endocrinology
36. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016
    Derek P. Chew, Ian A Scott, Louise Cullen, John Kerswell French, Tom G. Briffa, Philip A. Tideman, Stephen Woodruffe, Alistair Kerr, Maree Branagan, Philip E. Aylward · 2016 · Heart Lung and Circulation
37. 2023 ESC Guidelines for the management of acute coronary syndromes
    Robert A. Byrne, Xavier Rosselló, John Joseph Coughlan, Emanuele Barbato, Colin Berry, Alaide Chieffo, Marc J. Claeys, Gheorghe‐Andrei Dan, Marc Richard Dweck, Mary Galbraith et al. · 2023 · European Heart Journal Acute Cardiovascular Care
38. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
    Wadhera, Rishi K., Steen, Dylan L., Khan, Irfan, Giugliano, Robert P., Foody, JoAnne M. · 2016 · Journal of Clinical Lipidology
39. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
    Ron Cornelis Hoogeveen, Christie Mitchell Ballantyne · 2020 · Clinical Chemistry
40. Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation
    Richardson, Tom G., Leyden, Genevieve M., Wang, Qin, Bell, Joshua A., Elsworth, Benjamin, Davey Smith, George, Holmes, Michael V. · 2022 · PLOS Biology
41. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
42. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
    Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida et al. · 2023 · Journal of Atherosclerosis and Thrombosis
43. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
    Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A. et al. · 2019 · Endocrine Practice
44. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
    White, Jon, Swerdlow, Daniel I., Preiss, David, Fairhurst-Hunter, Zammy, Keating, Brendan J., Asselbergs, Folkert W., Sattar, Naveed, Humphries, Steve E., Hingorani, Aroon D., Holmes, Michael V. · 2016 · JAMA Cardiology
45. Pathophysiology and treatment of atherosclerosis
    Sandrin C. Bergheanu, Mathijs C. Bodde, J. Wouter Jukema · 2017 · Netherlands Heart Journal
46. Inflammatory and Cholesterol Risk in the FOURIER Trial
    Bohula, Erin A., Giugliano, Robert P., Leiter, Lawrence A., Verma, Subodh, Park, Jeong-Gun, Sever, Peter S., Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A. et al. · 2018 · Circulation
47. PCSK9: From Basic Science Discoveries to Clinical Trials
    Shapiro, Michael D., Tavori, Hagai, Fazio, Sergio · 2018 · Circulation Research
48. Lipid metabolism and carcinogenesis, cancer development.
    Jia Long, Chanjuan Zhang, Neng Zhu, Ke Du, Yufang Yin, Xi Tan, Duan‐Fang Liao, Qin Li · 2018 · Europe PMC (PubMed Central)
49. Lipid management in patients with chronic kidney disease
    Charles Joseph Ferro, Patrick Barry Mark, Mehmet Kanbay, Pantelis A. Sarafidis, Gunnar Henrik Heine, Patrick Rossignol, Ziad A. Massy, Francesca Mallamaci, José Manuel Valdivielso, Jolanta Małyszko et al. · 2018 · Nature Reviews Nephrology
50. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
    Mary P. McGowan, Seyed Hamed Hosseini Dehkordi, Patrick M. Moriarty, Paul Barton Duell · 2019 · Journal of the American Heart Association
51. The Evolving Future of PCSK9 Inhibitors
    Rosenson, Robert S., Hegele, Robert A., Fazio, Sergio, Cannon, Christopher P. · 2018 · Journal of the American College of Cardiology
52. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis
    Marston, Nicholas A., Giugliano, Robert P., Melloni, Giorgio E. M., Park, Jeong-Gun, Morrill, Valerie, Blazing, Michael A., Ference, Brian, Stein, Evan, Stroes, Erik S., Braunwald, Eugene et al. · 2022 · JAMA Cardiology
53. Effects of Icosapent Ethyl on Total Ischemic Events
    Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig et al. · 2019 · Journal of the American College of Cardiology
54. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
    Lipinski, Michael J., Benedetto, Umberto, Escarcega, Ricardo O., Biondi-Zoccai, Giuseppe, Lhermusier, Thibault, Baker, Nevin C., Torguson, Rebecca, Brewer, H. Bryan, Waksman, Ron · 2016 · European Heart Journal
55. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
    Handelsman, Yehuda, Jellinger, Paul S., Guerin, Chris K., Bloomgarden, Zachary T., Brinton, Eliot A., Budoff, Matthew J., Davidson, Michael H., Einhorn, Daniel, Fazio, Sergio, Fonseca, Vivian A. et al. · 2020 · Endocrine Practice
56. Cardiovascular risk assessment in patients with diabetes
    Marcello Casaccia Bertoluci, Viviane Zorzanelli Rocha · 2017 · Diabetology & Metabolic Syndrome
57. Polyphenol Health Effects on Cardiovascular and Neurodegenerative Disorders: A Review and Meta-Analysis
    Francesco Potì, Daniele Santi, Giorgia Spaggiari, Francesca Zimetti, Ilaria Zanotti · 2019 · International Journal of Molecular Sciences
58. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
    Konstantinos C. Koskinas, George C.M. Siontis, Raffaele Piccolo, Dimitris Mavridis, Lorenz Räber, François Mach, Stephan Windecker · 2017 · European Heart Journal
59. ESVM Guideline on peripheral arterial disease
    Ulrich Frank, Sigrid Nikol, J. J. F. Belch, Vinko Boc, Marianne Brodmann, P. Carpentier, Ali Chraim, Caitríona Canning, Evangelos P. Dimakakos, Anders Gottsäter et al. · 2019 · VASA
60. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)
    G.B. John Mancini, Steven K. Baker, Jean Bergeron, DAVID H. FITCHETT, Jiri J Frohlich, Jacques J. Genest, Milan Gupta, Robert Alexander Hegele, Dominic S. Ng, Glen J. Pearson et al. · 2016 · Canadian Journal of Cardiology
61. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
    Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie, de Ferranti, Sarah D. et al. · 2026 · JACC
62. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
63. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
    Christopher Paul Cannon, James A. de Lemos, Robert S. Rosenson, Christie Mitchell Ballantyne, Yuyin Liu, Qi Gao, Tamara Palagashvili, Shushama Alam, Katherine E. Mues, Deepak L. Bhatt et al. · 2021 · JAMA Cardiology
64. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque
    Abed Janoudi, Fadi Elias Shamoun, Jagadeesh Kumar Kalavakunta, George S. Abela · 2015 · European Heart Journal
65. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia
    Leopoldo Pérez de Isla, Rodrigo Alonso K, Gerald Francis Watts, Nelva Mata, Adriana Saltijeral Cerezo, Ovidio Muñiz-Grijalvo, Francisco J. Fuentes, José Luis Díaz-Díaz, Raimundo de Andrés, Daniel Zambón et al. · 2016 · Journal of the American College of Cardiology
66. Coronary heart disease risk: Low-density lipoprotein and beyond
    Gabriel E. Shaya, Thorsten Martin Leucker, Steven Richard Jones, Seth Shay Martin, Peter Paul Toth · 2021 · Trends in Cardiovascular Medicine
67. Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
    Joshua C. Denny, Lisa A. Bastarache, Dan M. Roden · 2016 · Annual Review of Genomics and Human Genetics
68. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
    Peter W.F. Wilson, Tamar S. Polonsky, Michael D. Miedema, Amit Khera, Andrzej Stanislaw Kosinski, Jeffrey T. Kuvin · 2018 · Journal of the American College of Cardiology
69. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial
    Ouchi, Yasuyoshi, Sasaki, Jun, Arai, Hidenori, Yokote, Koutaro, Harada, Kazumasa, Katayama, Yasuo, Urabe, Takao, Uchida, Yasufumi, Hayashi, Masaru, Yokota, Naoto et al. · 2019 · Circulation
70. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack
    Jesse Dawson, Yannick Béjot, Louisa Marguerite Christensen, Gian Marco De Marchis, Martin Dichgans, Guri Hagberg, Mirjam R. Heldner, Haralampos J. Milionis, Linxin Li, Francesca Romana Pezzella et al. · 2022 · European Stroke Journal
71. Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials
    Chiavaroli, Laura, Nishi, Stephanie K., Khan, Tauseef A., Braunstein, Catherine R., Glenn, Andrea J., Mejia, Sonia Blanco, Rahelić, Dario, Kahleová, Hana, Salas-Salvadó, Jordi, Jenkins, David J.A. et al. · 2018 · Progress in Cardiovascular Diseases
72. 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo‐Kyung Kim, Seung‐Hwan Lee, Jae‐Seung Yun, Jong Ha Baek, Junghyun Noh, Byung‐Wan Lee, Tae Jung Oh et al. · 2021 · Diabetes & Metabolism Journal
73. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
    Kausik Kumar Ray, Frederick Johan Raal, David G. Kallend, Mark J Jaros, Wolfgang Köenig, Lawrence A. Leiter, Ulf Landmesser, Gregory G. Schwartz, David Lawrence, Andrew Friedman et al. · 2022 · European Heart Journal
74. 9. Cardiovascular Disease and Risk Management
    American Diabetes Association · 2017 · Diabetes Care
75. 2023 Chinese guideline for lipid management
    Jian‐Jun Li, Shui‐Ping Zhao, Dong Hui Zhao, Guoping Lü, Daoquan Peng, Jing Liu, Zhen‐Yue Chen, Yuan‐Lin Guo, Na‐Qiong Wu, Sheng-kai Yan et al. · 2023 · Frontiers in Pharmacology
76. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
    Harold Edward Bays, Daniel Gaudet, Robert Weiss, Juan Lima Ruiz, Gerald Francis Watts, Ioanna Gouni‐Berthold, Jennifer G. Robinson, Jian M. Zhao, Corinne Hanotin, Stephen Donahue · 2015 · The Journal of Clinical Endocrinology & Metabolism
77. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents
    Paul M. Ridker, Samia Mora, Lynda M. Rose · 2016 · European Heart Journal
78. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
    Shapiro, Michael D., Fazio, Sergio · 2016 · Circulation Research
79. Disorders of lipid metabolism. Clinical Guidelines 2023
    Ежов Марат Владиславович, Valery V. Kukharchuk, И. В. Сергиенко, Asiiat S. Alieva, Mikhail Borisovich Antsiferov, Alexey A. Ansheles, Gurami G. Arabidze, Aronov Dm, G. P. Arutyunov, Н. М. Ахмеджанов et al. · 2023 · Russian Journal of Cardiology
80. Multicenter Cohort Study of Acute Myocardial Infarction in Korea – Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry –
    Ju Han Kim, Shung-Chull Chae, Dong Joo Oh, Hyo-Soo Kim, Young Jo Kim, Youngkeun Ahn, Myeong‐Chan Cho, Chong Jin Kim, Junghan Yoon, Hyun‐Young Park et al. · 2016 · Circulation Journal
81. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
    Karatasakis, Aris, Danek, Barbara A, Karacsonyi, Judit, Rangan, Bavana V, Roesle, Michele K, Knickelbine, Thomas, Miedema, Michael D, Khalili, Houman, Ahmad, Zahid, Abdullah, Shuaib et al. · 2017 · Journal of the American Heart Association
82. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
    Henry N. Ginsberg, Daniel James Rader, Frederick Johan Raal, John R. Guyton, Marie T. Baccara‐Dinet, Christelle Lorenzato, Robert C. Pordy, Erik S.G. Stroes · 2016 · Cardiovascular Drugs and Therapy
83. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
    Anne Grete Semb, Eirik Ikdahl, Grunde Wibetoe, Cynthia S. Crowson, Silvia Rollefstad · 2020 · Nature Reviews Rheumatology
84. 2024 Clinical practice guidelines for Hypertension in adults
    Ж. Д. Кобалава, А. О. Конради, Sergey Vladimirovich Nedogoda, Evgeny V. Shlyakhto, G. P. Arutyunov, Е. И. Баранова, О. Л. Барбараш, N. V. Bobkova, Sergey Anatol'evich Boytsov, Marina Gennad'evna Bubnova et al. · 2024 · Russian Journal of Cardiology
85. 2018 Guidelines for the management of dyslipidemia
    Eun‐Jung Rhee, Hyeon Chang Kim, Jae Hyeon Kim, Eun Young Lee, Byung Jin Kim, Eun Mi Kim, YoonJu Song, Jeong Hyun Lim, Byung Jin Kim, Seonghoon Choi et al. · 2019 · The Korean Journal of Internal Medicine
86. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol
    Xiao, Changting, Dash, Satya, Morgantini, Cecilia, Hegele, Robert A., Lewis, Gary F. · 2016 · Diabetes
87. Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms
    Guizheng Wei, Ke Lu, Muhammad Umar, Zhenglin Zhu, William W. Lu, John Roger Speakman, Yan Chen, Liping Tong, Di Chen · 2023 · Bone Research
88. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
    Murphy, Sabina A., Cannon, Christopher P., Blazing, Michael A., Giugliano, Robert P., White, Jennifer A., Lokhnygina, Yuliya, Reist, Craig, Im, KyungAh, Bohula, Erin A., Isaza, Daniel et al. · 2016 · Journal of the American College of Cardiology
89. Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70
    Bergmark, Brian A., Marston, Nicholas A., Bramson, Candace R., Curto, Madelyn, Ramos, Vesper, Jevne, Alexandra, Kuder, Julia F., Park, Jeong-Gun, Murphy, Sabina A., Verma, Subodh et al. · 2022 · Circulation
90. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey
    Željko Reiner, Guy De Backer, Zlatko Fras, Kornelia Kotseva, Lale S Tokgözoğlu, David Wood, Dirk De Bacquer · 2016 · Atherosclerosis
91. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
    Amand Floriaan Schmidt, Lucy S Pearce, John T. Wilkins, John P. Overington, Aroon Dinesh Hingorani, Juan Pablo Casas · 2017 · Cochrane Database of Systematic Reviews
92. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
    Robert Patrick Giugliano, Stephen D. Wiviott, Michael A. Blazing, Gaetano Maria De Ferrari, Jeong‐Gun Park, Sabina A. Murphy, Jennifer A. White, Andrew M. Tershakovec, Christopher Paul Cannon, Eugene Braunwald · 2017 · JAMA Cardiology
93. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
    Marc Steven Sabatine, Stephen D. Wiviott, KyungAh Im, Sabina A. Murphy, Robert Patrick Giugliano · 2018 · JAMA Cardiology
94. Atherothrombotic risk stratification and ezetimibe for secondary prevention
    Bohula, Erin A., Morrow, David A., Giugliano, Robert P., Blazing, Michael A., He, Ping, Park, Jeong-Gun, Murphy, Sabina A., White, Jennifer A., Kesaniemi, Y. Antero, Pedersen, Terje R. et al. · 2017 · Journal of the American College of Cardiology
95. Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update
    Liping Liu, Zixiao Li, Hongyu Zhou, Wanying Duan, Xiaochuan Huo, Weihai Xu, Shujuan Li, Ximing Nie, Huihui Liu, Jinjie Liu et al. · 2023 · Stroke and Vascular Neurology
96. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
    Banach, Maciej, Stulc, Tomas, Dent, Ricardo, Toth, Peter P. · 2016 · International Journal of Cardiology
97. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
    Robinson, Jennifer G., Rosenson, Robert S., Farnier, Michel, Chaudhari, Umesh, Sasiela, William J., Merlet, Laurence, Miller, Kathryn, Kastelein, John J.P. · 2017 · Journal of the American College of Cardiology
98. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond
    Yuichi Saito, Kazuma Oyama, Kenichi Tsujita, Satoshi Yasuda, Yoshio Kobayashi · 2022 · Journal of Cardiology
99. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial
    Vallejo-Vaz, Antonio J., Fayyad, Rana, Boekholdt, S. Matthijs, Hovingh, G. Kees, Kastelein, John J., Melamed, Shari, Barter, Philip, Waters, David D., Ray, Kausik K. · 2018 · Circulation
100. Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?
     James Yarmolinsky, Kaitlin Hazel Wade, Rebecca Claire Richmond, Ryan Langdon, Caroline J. Bull, Kate M. Tilling, Caroline L. Relton, Sarah Jane Lewis, George Davey Smith, Richard Michael Martin · 2018 · Cancer Epidemiology Biomarkers & Prevention